Treatment with Natalizumab in Relapsing–Remitting Multiple Sclerosis Patients Induces Changes in Inflammatory Mechanism

Natalizumab is a widely accepted drug for the relapsing–remitting subtype of multiple sclerosis (RRMS). The present longitudinal exploratory study in RRMS patients analyzes the effects of natalizumab treatment on the levels of pro-inflammatory and anti-inflammatory cytokine protein levels and also t...

Descripción completa

Detalles Bibliográficos
Autores principales: Ramos-Cejudo, Jaime, Oreja-Guevara, Celia, Stark Aroeira, Luiz, Rodriguez de Antonio, Luis, Chamorro, Beatriz, Diez-Tejedor, Exuperio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2011
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3155864/
https://www.ncbi.nlm.nih.gov/pubmed/21491095
http://dx.doi.org/10.1007/s10875-011-9522-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3155864/
https://www.ncbi.nlm.nih.gov/pubmed/21491095
http://dx.doi.org/10.1007/s10875-011-9522-x

Ejemplares similares